



## Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Corporate Update

May 2, 2023

VANCOUVER, British Columbia, May 02, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its first quarter 2023 financial and operating results after the close of U.S. financial markets on Tuesday, May 9, 2023.

### Conference Call/Webcast Information:

**Date:** Tuesday, May 9, 2023  
**Time:** 4:30 pm Eastern Time (1:30 pm Pacific Time)  
**Dial-In:** (800) 715-9871 or (646) 307-1963 for international callers  
**Conference ID:** 4092363

A live audio webcast will be available on the "[Investors](#)" section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change.

### About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit [www.xenon-pharma.com](http://www.xenon-pharma.com).

*"Xenon" and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.*

### Investor/Media Contact:

Jodi Regts  
Xenon Pharmaceuticals Inc.  
Phone: 604.484.3353  
Email: [investors@xenon-pharma.com](mailto:investors@xenon-pharma.com)



Source: Xenon Pharmaceuticals Inc.